Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

153.00GBp
26 Jan 2015
Change (% chg)

1.00p (+0.66%)
Prev Close
152.00p
Open
149.00p
Day's High
155.00p
Day's Low
149.00p
Volume
548,769
Avg. Vol
648,850
52-wk High
171.50p
52-wk Low
113.25p

VEC.L

Chart for VEC.L

About

Vectura Group plc (Vectura) is a developer of therapies principally for the treatment of respiratory diseases. The Company is engaged in developing treatments for respiratory diseases. Vectura’s products target diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The Company’s pharmaceutical business... (more)

Overall

Beta: -0.13
Market Cap(Mil.): £611.77
Shares Outstanding(Mil.): 402.48
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): -- 40.21 40.82
EPS (TTM): -0.02 -- --
ROI: -3.35 19.07 18.35
ROE: -3.65 19.85 19.25
Search Stocks

Britain's Vectura collaborates with Janssen in asthma, COPD

LONDON - Vectura Group, a respiratory drugs specialist, will work with Janssen Biotech to develop treatments for asthma and lung disease COPD, it said on Tuesday.

06 Jan 2015

Britain's Vectura collaborates with Janssen in asthma, COPD

LONDON, Jan 6 - Vectura Group, a respiratory drugs specialist, will work with Janssen Biotech to develop treatments for asthma and lung disease COPD, it said on Tuesday.

06 Jan 2015

BRIEF-Vectura signs global development and licence agreement with Janssen

* Vectura signs global development and licence agreement with Janssen in asthma/COPD

06 Jan 2015

BRIEF-Vectura's asthma drug meets main goal in mid-stage trial

* Investigational drug/device combination VR475 met primary endpoint and has shown significant clinical benefit in a phase IIb/III trial in severe asthma patients

11 Dec 2014

BRIEF-Vectura gets marketing nod for Airflusal Forspiro in Ireland and Czech Republic

* Approval in Ireland and Czech Republic for innovative respiratory inhaler airflusal forspiro

19 Nov 2014

BRIEF-Vectura names Andrew Oakley as CFO

* Oakley will succeed Paul Oliver as CFO, executive director, and company secretary effective from 1 January 2015 Source text for Eikon: Further company coverage:

18 Nov 2014

BRIEF-Vectura H1 rev up 14 pct

* Nva237 is expected to be filed in us by novartis in q4 2014 Source text for Eikon: Further company coverage:

18 Nov 2014

BRIEF-Vectura says partner Novartis signs marketing deal with Pfizer UK

* Announcement of commercial arrangement with Pfizer UK to promote Ultibro Breezhaler and Seebri Breezhaler in United Kingdom Source text for Eikon: Further company coverage:

04 Sep 2014

BRIEF-Vectura performance from April to date in line with board's expectations

* Product pipeline is progressing in line with board's expectations

19 Aug 2014

Earnings vs. Estimates

Search Stocks